Pages that link to "Q33800946"

The following pages link to Increase in Clostridium difficile-related mortality rates, United States, 1999-2004. (Q33800946):

Displaying 50 items.

• Antibiotic treatment for Clostridium difficile -associated diarrhea in adults (Q24234378) ‎ (← links)
• Amixicile, a novel inhibitor of pyruvate: ferredoxin oxidoreductase, shows efficacy against Clostridium difficile in a mouse infection model (Q24616179) ‎ (← links)
• Bench-to-bedside review: Clostridium difficile colitis (Q24644191) ‎ (← links)
• Toxin B is essential for virulence of Clostridium difficile (Q24647539) ‎ (← links)
• Diagnosis and treatment of acute or persistent diarrhea (Q24654895) ‎ (← links)
• Clostridium difficile Toxins A and B: Insights into Pathogenic Properties and Extraintestinal Effects (Q26751477) ‎ (← links)
• Recent advances in the understanding of antibiotic resistance in Clostridium difficile infection (Q26767079) ‎ (← links)
• Acid suppression and the risk of Clostridium difficile infection (Q26823599) ‎ (← links)
• Current Trends in the Epidemiology and Outcomes of Clostridium difficile Infection (Q26996462) ‎ (← links)
• Diagnosis of Clostridium difficile Infections in Children (Q28075324) ‎ (← links)
• Clostridium difficile infection: An overview of the disease and its pathogenesis, epidemiology and interventions (Q28743438) ‎ (← links)
• Antibiotic treatment for Clostridium difficile-associated diarrhoea in adults (Q30235446) ‎ (← links)
• Delirium and other clinical factors with Clostridium difficile infection that predict mortality in hospitalized patients (Q30300033) ‎ (← links)
• Clostridium difficile ribotype 027 is most prevalent among inpatients admitted from long-term care facilities. (Q30365997) ‎ (← links)
• Survey of C. difficile-Specific Infection Control Policies in Local Long-Term Care Facilities (Q30412521) ‎ (← links)
• Ribotype 027 Clostridium difficile infections with measurable stool toxin have increased lactoferrin and are associated with a higher mortality (Q30413111) ‎ (← links)
• Diarrhea, clostridium difficile, and intestinal inflammation in residents of a long-term care facility (Q30436153) ‎ (← links)
• The analysis of para-cresol production and tolerance in Clostridium difficile 027 and 012 strains (Q30475404) ‎ (← links)
• A mariner-based transposon system for in vivo random mutagenesis of Clostridium difficile (Q33519869) ‎ (← links)
• Postoperative Clostridium difficile-associated diarrhea (Q33915343) ‎ (← links)
• Thuricin CD, a posttranslationally modified bacteriocin with a narrow spectrum of activity against Clostridium difficile. (Q33927147) ‎ (← links)
• Genome mining for radical SAM protein determinants reveals multiple sactibiotic-like gene clusters. (Q33961416) ‎ (← links)
• Preoperative risk factors for postoperative Clostridium difficile infection in colectomy patients. (Q33993544) ‎ (← links)
• The role of toxin A and toxin B in Clostridium difficile-associated disease: Past and present perspectives. (Q34006236) ‎ (← links)
• Epidemiology of Clostridium difficile infection (Q34027474) ‎ (← links)
• Lack of association of outcomes with treatment duration and microbiologic susceptibility data in Clostridium difficile infections in a non-NAP1/BI/027 setting (Q34072892) ‎ (← links)
• Inhibiting the Initiation ofClostridium difficileSpore Germination using Analogs of Chenodeoxycholic Acid, a Bile Acid (Q34150754) ‎ (← links)
• Current status of Clostridium difficile infection epidemiology (Q34285444) ‎ (← links)
• An optimized, synthetic DNA vaccine encoding the toxin A and toxin B receptor binding domains of Clostridium difficile induces protective antibody responses in vivo (Q34298763) ‎ (← links)
• The association between histamine 2 receptor antagonist use and Clostridium difficile infection: a systematic review and meta-analysis. (Q34331595) ‎ (← links)
• A hospital-based study of the clinical characteristics of Clostridium difficile infection in children (Q34440654) ‎ (← links)
• Identification of a Genetic Locus Responsible for Antimicrobial Peptide Resistance in Clostridium difficile (Q34484594) ‎ (← links)
• Characterisation of Clostridium difficile biofilm formation, a role for Spo0A. (Q34510386) ‎ (← links)
• Association between proton pump inhibitor therapy and clostridium difficile infection: a contemporary systematic review and meta-analysis (Q34510524) ‎ (← links)
• Procalcitonin levels associate with severity of Clostridium difficile infection (Q34625689) ‎ (← links)
• Clostridium difficile: progress and challenges (Q34625939) ‎ (← links)
• Trends in gastroenteritis-associated mortality in the United States, 1985-2005: variations by ICD-9 and ICD-10 codes (Q34707949) ‎ (← links)
• Treatment of Clostridium difficile infection: recent trial results (Q34710368) ‎ (← links)
• Hypoxia-inducible factor signaling provides protection in Clostridium difficile-induced intestinal injury (Q34717238) ‎ (← links)
• Bile acid recognition by the Clostridium difficile germinant receptor, CspC, is important for establishing infection. (Q34722536) ‎ (← links)
• Upregulation of the host SLC11A1 gene by Clostridium difficile toxin B facilitates glucosylation of Rho GTPases and enhances toxin lethality (Q34729613) ‎ (← links)
• Rapid stool-based diagnosis of Clostridium difficile infection by real-time PCR in a children's hospital (Q34741501) ‎ (← links)
• Determinants of Clostridium difficile Infection Incidence Across Diverse United States Geographic Locations (Q34801846) ‎ (← links)
• An agent-based simulation model for Clostridium difficile infection control (Q35031203) ‎ (← links)
• Bowel preparation for colectomy and risk of Clostridium difficile infection (Q35037050) ‎ (← links)
• Adherence to and Outcomes Associated with a Clostridium difficile Guideline at a Large Teaching Institution (Q35063103) ‎ (← links)
• Epidemiology of Clostridium difficile infection among active duty United States military personnel (1998-2010). (Q35076928) ‎ (← links)
• Aging and infectious diseases: workshop on HIV infection and aging: what is known and future research directions (Q35088160) ‎ (← links)
• In Vitro Selection of a Single-Stranded DNA Molecular Recognition Element against Clostridium difficile Toxin B and Sensitive Detection in Human Fecal Matter (Q35103196) ‎ (← links)
• Future novel therapeutic agents for Clostridium difficile infection (Q35175136) ‎ (← links)